Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 201 ~ 220 of 25713, Page 11 of 1287
201. Unapproved Therapies Cause Significantly More Patient Injuries Than Reported by Cell Therapy Clinics
A team of ophthalmologists went looking for scientific evidence in support of commercially available “cell therapy” for eye diseases. Not only did they find virtually none; they instead discovered a growing number of patients are being irreparably harmed by unapproved cell therapies.
10/29/2018 American Academy of Ophthalmology
202. American Academy of Ophthalmology Announces $2 million gift to Advance Childhood Eye Disease Research
The American Academy of Ophthalmology today announced a $2 million gift from the Knights Templar Eye Foundation (KTEF) to establish a permanent research fund to advance the practice of pediatric ophthalmology.
10/28/2018 American Academy of Ophthalmology
203. Evidence Mounts That an Eye Scan May Detect Early Alzheimer’s Disease
Results from two studies show that a new, non-invasive imaging device can see signs of Alzheimer’s disease in a matter of seconds.
10/28/2018 American Academy of Ophthalmology
204. Diabetes Medication May Protect Against a Common Cause of Blindness
Researchers from Taiwan have shown that people with type 2 diabetes who took a common diabetes medication, metformin, had a significantly lower rate of age-related macular degeneration. The study suggests that the anti-inflammatory and anti-oxidative effects of metformin can protect against AMD while it controls diabetes.
10/28/2018 American Academy of Ophthalmology
205. American Academy of Ophthalmology Honors Luminaries in Medical and Surgical Eye Care
The American Academy of Ophthalmology is honoring exceptional ophthalmologists whose contributions have improved patient care and advanced the profession in the field of medical and surgical eye care will be honored at AAO 2018, the Academy’s 122nd annual meeting in Chicago.
10/28/2018 American Academy of Ophthalmology
206. American Academy of Ophthalmology Announces $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Health
The American Academy of Ophthalmology today announced a project to construct the world’s first public museum dedicated to vision and eye health. The new museum will be located in San Francisco.
10/27/2018 American Academy of Ophthalmology
207. Easier, Potentially More Effective Treatment for Blinding Eye Disease Shows Promise in Clinical Trial
A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments.
10/26/2018 American Academy of Ophthalmology
208. Physicians have immunity for good-faith psychiatric discharges
One day after being discharged from involuntary commitment in a mental health facility, a Maryland man killed himself a sequence of events that everyone fears. But psychiatrists acting in good faith in their decision making in such cases have immunity from medical liability in the event of adverse outcomes, Maryland뭩 highest court has ruled.
10/26/2018 American Medical Association (AMA) News by Tanya Albert Henry
209. Flu mutations in a single cell help to predict immune response
Genetic diversity of the virus may explain variability in how well a cell fights back.
10/26/2018 Nature News by Carrie Arnold
210. The overlooked benefits of medical scribes
It''s a given that using medical scribes will reduce data-entry time for physicians. But the myriad benefits this produces for patients and physicians are now being quantified by emerging research.
10/26/2018 American Medical Association (AMA) News by Andis Robeznieks
211. New global commitment to primary health care for all at Astana conference
Declaration of Astana charts course to achieve universal health coverage, 40 years since declaration on primary health care in Alma-Ata
10/25/2018 World Health Organization (WHO)
212. Merck Announces Third-Quarter 2018 Financial Results
Third-Quarter 2018 Worldwide Sales Were $10.8 Billion / Third-Quarter 2018 GAAP EPS was $0.73, Third-Quarter Non-GAAP EPS was $1.19 / Company Narrows 2018 Full-Year Revenue Range to be Between $42.1 Billion and $42.7 Billion, Including a Minimal Impact from Foreign Exchange / Results from KEYNOTE-426 Studying KEYTRUDA in Combination with Axitinib as First-line Treatment for Advanced or Metastatic Renal Cell Carcinoma Met Primary Endpoints of Overall Survival and Progression-Free Survival / Company Announces 15 Percent Increase to Quarterly Dividend to 55 Cents Per Outstanding Share and Authorizes an Additional $10 Billion Share Repurchase, Including a $5 Billion Accelerated Share Repurchase Program
10/25/2018 MERCK
213. Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
ABBOTT PARK, Ill., Oct. 25, 2018 /PRNewswire/ Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing1,2. These new assays enable the fastest-ever3 time to molecular influenza A & B and Strep A results at the point of care.4 Currently available on the ID NOW™ platform (formerly Alere i), both assays have been granted a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver.
10/25/2018 Abbott
214. Privacy, security guidelines aim to bolster use of mHealth
Privacy and security guidelines aimed at securing the protected health information and personal, identifiable data of mobile health app users have been released for public comment by Xcertia, a nonprofit founded by the AMA and other major health and technology organizations.
10/25/2018 American Medical Association (AMA) News by Andis Robeznieks
215. AMA Announces Updated Tool to Locate Underserved Patient Care Areas
Latest version of geospatial mapping tool could be used to assist reporters or researchers hoping to understand trends and gaps in patient access to care.
10/25/2018 American Medical Association
216. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial
This randomized clinical trial compares the effect of adding the somatostatin analogue lanreotide to standard care vs standard care alone on change in estimated glomerular filtration rate (eGFR) in patients with autosomal dominant polycystic kidney disease (PCKD).
10/25/2018 JAMA 2018 doi:10.1001/jama.2018.15870
217. Survey reveals top 6 challenges faced in medical residency
For three in five medical residents, nonclinical concerns such as work-life balance, time pressures or debt represent their biggest challenge during in training.
10/25/2018 American Medical Association (AMA) News by Brendan Murphy
218. Strict EU ruling on gene edited crops squeezes science
Researchers are feeling the pinch and demanding exemptions for plant science and agriculture.
10/25/2018 Nature News by Andrew J Wight
219. Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization
Increases Quarterly Dividend 15% to $0.55 per Outstanding Share Enters Into a $5 Billion Accelerated Share Repurchase Program Under Expanded Authorization
10/25/2018 MERCK
220. FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain
(GLOBE NEWSWIRE via COMTEX) --myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician
10/24/2018 Medtronic
11 12 13 14 15 16 17 18 19 20
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱